Paclitaxel is one of the most effective and well tolerated anti-cancer drugs used for advanced metastatic breast����cancer treatment. We treated a 70-year-old woman with metastatic breast cancer who had developed Stevens-Johnsonsyndrome after intravenous administration of the first dose of paclitaxel. Stevens-Johnson syndrome is a rare, severe,immune-mediated cutaneous reaction to medication. Drug lymphocyte stimulation test���� was performed and Paclitaxel waslikely to be a cause of this complication . The patient was treated with steroid pulse therapy with intravenousimmunoglobulin. This case report serves as an alert for the need to observe patients carefully for potentially severe cutaneousreactions to paclitaxel.